Latest Breaking News On - Vor biopharma inc - Page 1 : comparemela.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04.06.2024 - CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock .

United kingdomSarah spencerVor biopharma incCompensation committee of the board directorsVor bioNasdaq listing ruleVor biopharmaInducement plan

Vor Biopharma s (VOR) Outperform Rating Reaffirmed at Oppenheimer

Vor Biopharma s (VOR) Outperform Rating Reaffirmed at Oppenheimer
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel nicolausSg americas securitiesExchange traded conceptsVanguard group incAcadian asset managementVor biopharma company profileVor biopharma incVor biopharmaFree reportGet free reportTraded conceptsBiopharma incVor biopharma daily

Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Stifel nicolausSecurities exchange commissionVor biopharma incSg americas securitiesVor biopharmaGet free reportBiopharma stock downFree reportBiopharma incVor biopharma daily

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSarah spencerVor biopharma incCompensation committee of the board directorsCompensation committeeVor bioNasdaq listing ruleVor biopharmaInducement plan

Vor Biopharma s (VOR) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Tuesday, Benzinga reports. Wedbush currently has a $11.00 price target on the stock. A number of other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus reduced their target price on […]

Stifel nicolausVor biopharma incExchange traded conceptsSecurities exchange commissionVor biopharmaFree reportBiopharma stock downGet free reportTraded conceptsBiopharma incVor biopharma daily